## 1-Palmitoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine (PDPC): A Phospholipid with Significance
**1-Palmitoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine (PDPC)** is a **phospholipid** – a type of fat molecule found in cell membranes. It's specifically a **glycerophospholipid**, meaning it contains a glycerol backbone, two fatty acid chains, and a phosphate group linked to a choline molecule.
**Here's what makes PDPC unique:**
* **Docosahexaenoic acid (DHA) is one of the fatty acids:** DHA is an omega-3 fatty acid that's crucial for brain development, vision, and heart health. Its presence in PDPC makes it particularly interesting for research.
* **Palmitic acid is the other fatty acid:** Palmitic acid is a saturated fatty acid that provides structure and stability to cell membranes.
* **Specific molecular structure:** The 'sn' designation indicates a specific stereochemical arrangement of the glycerol molecule, which influences the way the molecule interacts with other lipids and proteins.
**Why is PDPC important for research?**
PDPC is increasingly studied because of its potential role in various biological processes, including:
* **Brain function:** DHA is a major component of brain cell membranes, and PDPC's presence in the brain suggests it plays a role in neuronal function, communication, and plasticity.
* **Inflammation:** PDPC has been shown to modulate inflammatory responses, potentially offering therapeutic potential in inflammatory conditions.
* **Cardiovascular health:** DHA has beneficial effects on cardiovascular health, and PDPC's presence in the heart may contribute to its protective functions.
* **Cancer research:** Some studies suggest that PDPC might have anticancer properties, potentially affecting tumor growth and development.
**Research areas:**
* **Neuroscience:** Investigating PDPC's impact on brain development, cognitive function, and neurodegenerative diseases.
* **Immunology:** Exploring PDPC's role in immune responses and inflammation.
* **Nutrition:** Studying the dietary sources of PDPC and its potential benefits for health.
* **Pharmacology:** Developing new drugs that target or manipulate PDPC's function for therapeutic purposes.
**Overall, 1-palmitoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine is a fascinating phospholipid with potential implications for various fields of research. Understanding its structure, function, and interaction with other molecules will provide valuable insights into fundamental biological processes and offer opportunities for therapeutic development.**
1-hexadecanoyl-2-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycero-3-phosphocholine : A phosphatidylcholine 38:6 in which the acyl groups at C-1 and C-2 are specified as hexadecanoyl and (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl respectively. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 6441886 |
| CHEBI ID | 74963 |
| SCHEMBL ID | 2126229 |
| MeSH ID | M0102679 |
| Synonym |
|---|
| pdpc |
| palmitoyldocosahexaenoylphosphatidylcholine |
| palmitoyldocosahexaenoyl phosphatidylcholine |
| [(2r)-2-[(4z,7z,10z,13z,16z,19z)-docosa-4,7,10,13,16,19-hexaenoyl]oxy-3-hexadecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate |
| SCHEMBL2126229 |
| phosphatidylcholine(38:6) |
| pc(38:6) |
| pdch-gpc |
| (cd3-16.0)(22.6)pc |
| 3,5,8-trioxa-4-phosphatriaconta-12,15,18,21,24,27-hexaen-1-aminium, 4-hydroxy-n,n,n-trimethyl-9-oxo-7-(((1-oxohexadecyl)oxy)methyl)-, hydroxide, inner salt, 4-oxide, (r-(all-z))- |
| 1-(16,16,16-trideuteriopalmitoyl)-2-docosahexaenoyl-sn-glycero-3-phosphocholine |
| 1-palmitoyl-2-docosahexaenoylphosphatidylcholine |
| 59403-54-2 |
| 1-palmitoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine |
| pc(16:0/22:6(4z,7z,10z,13z,16z,19z)) |
| 1-hexadecanoyl-2-(4z,7z,10z,13z,16z,19z-docosahexaenoyl)-sn-glycero-3-phosphocholine |
| LMGP01012137 |
| 1-hexadecanoyl-2-(4z,7z,10z,13z,16z,19z)-docosahexaenoyl-sn-glycero-3-phosphocholine |
| CHEBI:74963 |
| 1-palmitoyl-2-(4z,7z,10z,13z,16z,19z)-docosahexaenoyl-sn-glycero-3-phosphocholine |
| pc(16:0/22:6omega3) |
| (2r)-2-[(4z,7z,10z,13z,16z,19z)-docosa-4,7,10,13,16,19-hexaenoyloxy]-3-(palmitoyloxy)propyl 2-(trimethylazaniumyl)ethyl phosphate |
| phosphatidylcholine(16:0/22:6) |
| 1-palmitoyl-2-docosahexaenoyl-gpc |
| 1-c16:0-2-c22:6(omega-3)-phosphatidylcholine |
| 1-palmitoyl-2-docosahexaenoyl-gpc (16:0/22:6) |
| phosphatidylcholine(16:0/22:6omega3) |
| gpc(16:0/22:6) |
| IESVDEZGAHUQJU-ZLBXKVHBSA-N |
| 16:0-22:6 pc |
| pc(16:0_22:6) |
| HY-126354 |
| Q27105028 |
| CS-0102937 |
| DTXSID001198216 |
| AKOS040733954 |
| PD133614 |
| Role | Description |
|---|---|
| mouse metabolite | Any mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus). |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| phosphatidylcholine 38:6 | A 1,2-diacyl-sn-glycero-3-phosphocholine in which the acyl groups at C-1 and C-2 contain 38 carbons in total with 6 double bonds. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Pathway | Proteins | Compounds |
|---|---|---|
| Phosphatidylcholine Biosynthesis PC(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) | 6 | 20 |
| Phosphatidylethanolamine Biosynthesis PE(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) | 5 | 16 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 2 (16.67) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.28) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 12 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||